Altuvoct clotting factor for Welsh patients comes from Sobi
- Velindre University NHS Trust
- Wales
- Direct award
- 27 October 2026 to 17 August 2028
Velindre University NHS Trust is buying Altuvoct (efanesoctocog alfa), a recombinant clotting factor medicine, from Swedish Orphan Biovitrum (Sobi).
NICE has approved the medicine, but it is not available through the Bleeding Disorders Framework run by NHS England. The trust's contract gives Welsh patients access to it while Sobi negotiates a deal with NHS England.
The trust awarded the supply directly to Sobi in October 2026. It is worth £270,000 and runs to August 2028.
Contract ends August 2028
- What
- Medicines supply
- Supplier
- Swedish Orphan Biovitrum (Sobi)
- Value
- £270,000
- How it was bought
- Direct award
- Dates and next
- Oct 2026 to Aug 2028